This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)

Tipranks - Tipranks - Thu Aug 6, 6:14AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO).

Claim 55% Off TipRanks

Pfizer (PFE)

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer today. The company’s shares closed last Tuesday at $25.41, close to its 52-week low of $24.48.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 14.2% and a 58.7% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.63, which is a 14.3% upside from current levels. In a report released yesterday, TipRanks – PerPlexity also downgraded the stock to Hold with a $27.00 price target.

See the top stocks recommended by analysts >>

Ultragenyx Pharmaceutical (RARE)

Citi analyst Yigal Nochomovitz maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $45.00. The company’s shares closed last Tuesday at $25.81.

According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of 13.7% and a 48.4% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as ArriVent BioPharma, Inc., EyePoint Pharmaceuticals, and Lexicon Pharmaceuticals. ;'>

Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $53.50, representing an 112.4% upside. In a report issued on July 27, Bank of America Securities also maintained a Buy rating on the stock.

Allogene Therapeutics (ALLO)

William Blair analyst Sami Corwin maintained a Buy rating on Allogene Therapeutics today. The company’s shares closed last Tuesday at $1.90.

According to TipRanks.com, Corwin is a 5-star analyst with an average return of 18.4% and a 54.6% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., Crispr Therapeutics AG, and Zevra Therapeutics. ;'>

Allogene Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.00.

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).